Search This Blog

Monday, June 17, 2019

Bio-Techne nabs accelerated review in U.S. for ExoDx EPI test

The FDA has granted Breakthrough Device Designation to Bio-Techne’s (NASDAQ:TECH) ExoDx Prostate IntelliScore (EPI) test.
Breakthrough Device status provides for more intensive guidance on development and accelerated review of the marketing application.
This designation also marks a milestone in the advancement of the company’s patented technology platform.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)